11月26日，A股三大指数集体上涨，截至午间收盘，沪指涨0.14%，深证成指涨1.61%，创业板指涨2.76%，北证50指数涨0.40%，沪深京三市半日成交 11439亿元，较上个交易日同期缩量392亿元。全市场超2800只个股上涨。 | | | | 卖1 | | | | --- | --- | --- | --- | --- | --- | | | | | 买1 | | 2.81 74.6 万 | | | | | 买2 | 2.80 | 3800 | | | | | 录3 | 2.79 | 726 | | 2.29 | | -10.20% | 址 d | 2.78 | 1579 | | 成交额 2.31亿 | | | 买5 | 2.77 | 1048 | | 4932万 | | | | 分时成交 ▲ | | | | | 7 | 11:29 | 2.81 | 43 | | | | | 11:29 | 2.81 | 38 | | | | | 11:29 | 2.81 | 2 | | 分时博弈 | 超大:1.357大户 :- 0.161中户 :- 0.578 小户 :- 0.618 | | 11:29 | 2.8 ...

格隆汇11月25日丨珍宝岛(603567.SH)在投资者互动平台表示，公司针对甲型、乙型流感的治疗药物有 注射用炎琥宁、复方芩兰口服液、小儿热速清糖浆、双黄连口服液、双黄连注射液和注射用双黄连等， 均为在产在售产品。 ...

格隆汇11月25日丨珍宝岛(603567.SH)在投资者互动平台表示，公司针对甲型、乙型流感的治疗药物有 注射用炎琥宁、复方芩兰口服液、小儿热速清糖浆、双黄连口服液、双黄连注射液和注射用双黄连等， 均为在产在售产品。 ...

Core Viewpoint - The 90th National Pharmaceutical Trade Fair showcased Heilongjiang Zhenbaodao Pharmaceutical Co., Ltd., highlighting its brand, high-value product matrix, and ecological win-win philosophy [3][4] Group 1: Product Showcase - Zhenbaodao Pharmaceutical exhibited high-quality product lines focusing on cardiovascular, respiratory, and anti-infection treatment areas, including key products like Injection Blood Setong 100mg and Xuechuang Capsule [3] - The company has developed a dual-driven system of "Traditional Chinese Medicine + Chemical Medicine," featuring products such as Compound Qilan Oral Liquid and Injection Ammonium Bromide [3] Group 2: Marketing Strategy - The company emphasized its 2025 "Guangshen Tuo" marketing strategy, which segments regional markets based on product attributes and promotes a model of "recruiting merchants, finding merchants, and servicing merchants" to enhance terminal coverage and sales efficiency [4] - Zhenbaodao Pharmaceutical established a three-tier academic promotion system, integrating medical, market, and data teams to monitor industry trends and provide precise marketing strategies [4] Group 3: Collaborative Ecosystem - The participation in the trade fair demonstrated the company's competitive product pipeline and industrial layout, aiming to build a comprehensive ecosystem of strategic collaboration, resource sharing, and value co-creation [4] - The company plans to continue driving innovation and collaboration, positioning itself to lead the pharmaceutical industry towards higher value creation [4]